ALPK1 agonists ignite innate immunity in anticancer therapy
Abstract
A recent study published in Nature by Tian et al. identifies UDSP-Hep as a synthetic agonist of the innate immune receptor Alpha-protein kinase 1 (ALPK1) that induces enhanced antitumor activity compared with the canonical ALPK1 agonist ADP-Hep and Toll-like receptor or stimulator of interferon genes agonists. UDSP-Hep drives the tumor microenvironment toward a proinflammatory, antitumor state.
Fields of Study & Subjects
Immune Response and Inflammation
interferon and immune responses
NF-κB Signaling Pathways
Publication details
- Journal / source
- Trends in cancer
- Publisher
- Elsevier BV
- Volume
- 12
- Issue
- 3
- Pages
- 209–211
- Publication date
- 26 February 2026
- Language
- EN